Jeong Hyehyun, Kim Sung-Bae
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea.
Ther Adv Med Oncol. 2023 Sep 29;15:17588359231200457. doi: 10.1177/17588359231200457. eCollection 2023.
In recent years, endocrine therapy (ET), an effective systemic treatment for the management of estrogen receptor (ER)-positive breast cancers, has regained interest as a neoadjuvant therapy based on evidence that ET can fulfill the aim of neoadjuvant systemic treatment for tumor shrinkage as well as elucidate important clinical information on endocrine sensitivity that enables the prognostication of patients. Moreover, neoadjuvant endocrine therapy (NET) potentially provides an opportunity for early assessment of the clinical efficacy of novel agents. Furthermore, recently reported trials have generated evidence for a more tailored approach for perioperative management of ER-positive breast cancer using clinical and molecular biomarkers, and this has provided a rationale that enables the broadening of clinical indications for NET. This review discusses the current evidence for NET, the evolution of NET trials, clinical indications, and NET-based treatment strategies.
近年来，内分泌治疗（ET）作为雌激素受体（ER）阳性乳腺癌的一种有效全身治疗方法，基于其能实现新辅助全身治疗使肿瘤缩小的目标以及阐明有关内分泌敏感性的重要临床信息从而实现患者预后评估的证据，重新引起了人们对其作为新辅助治疗的兴趣。此外，新辅助内分泌治疗（NET）有可能为新型药物的临床疗效早期评估提供机会。此外，最近报道的试验为使用临床和分子生物标志物对ER阳性乳腺癌进行围手术期管理提供了更具针对性的方法的证据，这为扩大NET的临床适应症提供了理论依据。本综述讨论了NET的现有证据、NET试验的演变、临床适应症以及基于NET的治疗策略。
